Merck KGaA
MKGAFOTCHealthcare● Active
$159.71
$-4.07(-2.48%)
Market Cap$69.4B
P/E Ratio—
52W High$161.65
52W Low$116.68
Merck KGaA (MKGAF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MKGAF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
$2.44
Est. $2.25 · +8.4%
Revenue
$5.93B
Est. $5.85B · +1.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
MKGAF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $2.32 | — | — | — | $6.10B | — |
| ▲ Q2 FY2026 | May 13, 2026 | $2.25 | $2.44 | +8.4% | $5.93B | $5.85B | +1.4% |
| ▼ Q1 FY2026 | Mar 5, 2026 | $2.29 | $2.21 | -3.5% | $6.17B | $6.19B | -0.4% |
| ▼ Q4 FY2025 | Nov 12, 2025 | $2.59 | $2.42 | -6.6% | $6.23B | $6.15B | +1.3% |
| ▼ Q3 FY2025 | Aug 7, 2025 | $2.52 | $1.77 | -29.8% | $6.19B | $6.14B | +0.7% |
| ▼ Q2 FY2025 | May 15, 2025 | $2.34 | $1.85 | -20.9% | $5.79B | $5.97B | -3.0% |
| ▼ Q1 FY2025 | Mar 6, 2025 | $2.23 | $1.59 | -28.7% | $5.61B | $5.76B | -2.5% |
| ▼ Q4 FY2024 | Nov 14, 2024 | $2.52 | $2.04 | -19.1% | $5.78B | $5.93B | -2.7% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$2.32
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
$2.44
EPS Est.
$2.25
EPS Surpr.
+8.4%
Revenue
$5.93B
Q1 FY2026
Mar 5, 2026Miss
EPS Actual
$2.21
EPS Est.
$2.29
EPS Surpr.
-3.5%
Revenue
$6.17B
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
$2.42
EPS Est.
$2.59
EPS Surpr.
-6.6%
Revenue
$6.23B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
$1.77
EPS Est.
$2.52
EPS Surpr.
-29.8%
Revenue
$6.19B
Q2 FY2025
May 15, 2025Miss
EPS Actual
$1.85
EPS Est.
$2.34
EPS Surpr.
-20.9%
Revenue
$5.79B
Q1 FY2025
Mar 6, 2025Miss
EPS Actual
$1.59
EPS Est.
$2.23
EPS Surpr.
-28.7%
Revenue
$5.61B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
$2.04
EPS Est.
$2.52
EPS Surpr.
-19.1%
Revenue
$5.78B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $1.80 | $1.83 | $1.86 | 1 |
| Q3 FY2026 | $2.00 | $2.04 | $2.07 | 1 |
| Q2 FY2026 | $1.98 | $2.01 | $2.05 | 1 |
| Q1 FY2026 | $1.92 | $1.95 | $1.99 | 1 |
| Q4 FY2025 | $1.91 | $1.95 | $1.98 | 1 |
| Q3 FY2025 | $2.17 | $2.21 | $2.25 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $5.3B | $5.3B | $5.4B | 2 |
| Q3 FY2026 | $5.3B | $5.4B | $5.4B | 3 |
| Q2 FY2026 | $5.2B | $5.3B | $5.4B | 3 |
| Q1 FY2026 | $5.0B | $5.1B | $5.2B | 4 |
| Q4 FY2025 | $5.2B | $5.3B | $5.3B | 4 |
| Q3 FY2025 | $5.2B | $5.2B | $5.3B | 7 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +8.4% | $132.50 | $147.49 | +11.31% |
| ▼ Q1 FY2026 | Mar 5, 2026 | -3.5% | $145.71 | $133.90 | -8.11% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -6.6% | $129.51 | $130.59 | +0.83% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -29.8% | $124.50 | $124.39 | -0.09% |
| ▼ Q2 FY2025 | May 15, 2025 | -20.9% | $140.21 | $131.25 | -6.39% |
| ▼ Q1 FY2025 | Mar 6, 2025 | -28.7% | $150.45 | $147.90 | -1.69% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -19.1% | $156.35 | $152.00 | -2.78% |
| ▼ Q3 FY2024 | Aug 1, 2024 | -31.4% | $185.97 | $182.00 | -2.13% |
Q2 FY2026+11.31%
Report Date
May 13, 2026
EPS Beat/Miss
+8.4%
Price Before
$132.50
Price After
$147.49
Q1 FY2026-8.11%
Report Date
Mar 5, 2026
EPS Beat/Miss
-3.5%
Price Before
$145.71
Price After
$133.90
Q4 FY2025+0.83%
Report Date
Nov 12, 2025
EPS Beat/Miss
-6.6%
Price Before
$129.51
Price After
$130.59
Q3 FY2025-0.09%
Report Date
Aug 7, 2025
EPS Beat/Miss
-29.8%
Price Before
$124.50
Price After
$124.39
Q2 FY2025-6.39%
Report Date
May 15, 2025
EPS Beat/Miss
-20.9%
Price Before
$140.21
Price After
$131.25
Q1 FY2025-1.69%
Report Date
Mar 6, 2025
EPS Beat/Miss
-28.7%
Price Before
$150.45
Price After
$147.90
Q4 FY2024-2.78%
Report Date
Nov 14, 2024
EPS Beat/Miss
-19.1%
Price Before
$156.35
Price After
$152.00
Q3 FY2024-2.13%
Report Date
Aug 1, 2024
EPS Beat/Miss
-31.4%
Price Before
$185.97
Price After
$182.00
Avg Beat Reaction+11.31%
Avg Miss Reaction-2.91%
Beat Rate1 / 8 quarters
Largest Move+11.31% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MKGAF ends December
Merck KGaA (MKGAF) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $2.44 — beating the analyst consensus of $2.25 by +8.4%. The next MKGAF earnings date is expected around September 1, 2026.
Each quarter, investors track MKGAF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MKGAF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MKGAF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MKGAF earnings · 5 questionsMerck KGaA's next earnings report is expected around September 1, 2026. MKGAF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MKGAF historically reports after market close (AMC).
MKGAF earnings datewhen is MKGAF earningsMKGAF next earnings datewhen does MKGAF report earningsMKGAF earnings calendar
▸ Source: FMP · Merck KGaA SEC filings · US GAAP · Merck KGaA SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026